| Autor: |
Xie Z; Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.; Graduate University of Chinese Academy of Sciences, Beijing 100049, China., Liu B; Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China., Wang H; Department of Organic and Biomolecular Chemistry, University of Göttingen, Göttingen D-37077, Germany., Yang S; Chemical Biological Research Institute, College of Science, Northwest A & F University, Yangling 712100, China., Zhang H; Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China.; Graduate University of Chinese Academy of Sciences, Beijing 100049, China., Wang Y; Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China., Ji N; Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China., Qin S; Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai 264003, China., Laatsch H; Department of Organic and Biomolecular Chemistry, University of Göttingen, Göttingen D-37077, Germany. |
| Abstrakt: |
Kiamycin (1), a new angucyclinone derivative possessing an 1,12-epoxybenz[a]anthracene ring system, was isolated from the marine Streptomyces sp. strain M268 along with the known compounds 8-O-methyltetrangomycin (3) and 8-O-methylrabelomycin (4). Their structures were elucidated by detailed spectroscopic analysis and comparison with literature data. The new angucyclinone derivative showed inhibitory activities against the human cell lines HL-60 (leukemia), A549 (lung adenocarcinoma), and BEL-7402 (hepatoma) with inhibition rates of 68.2%, 55.9%, and 31.7%, respectively, at 100 µM. It appears to have potential as an anticancer agent with selective activity. |
